Sanctions or Suffering? Marc Botenga, representing The Left, probes the European Commission's assurances that EU sanctions against Iran avoid harming ordinary Iranians. His sharp inquiry challenges the Commission's claim amid mounting scientific studies detailing how sanctions have hampered medical supplies crucial for chronic and life-threatening illnesses. Patients with cancer, asthma, and rare blood disorders reportedly face shortages, while insulin and critical medicines become scarce. Needless to say, health advocates, affected Iranian civilians, pharmaceutical suppliers, humanitarian groups, and EU financial institutions are all eyes and ears for answers.

A Question from Parliament

Botenga’s pointed query stems from an October 2025 European Parliament session debate where conflicting views on sanctions' humanitarian consequences surfaced. His formal question demands the Commission elucidate how it ensures sanctions do not impact public health and requests any counter-evaluations to existing research showing material harm.

Concrete Commitments or Vague Assurances?

The Commission, responding through Ms. Albuquerque, reiterates sanctions target only Iran's nuclear ambitions and state behaviors, exempting humanitarian goods such as food and medicine. While emphasizing exceptions allowing aid delivery, the reply stops short of addressing specific medical shortages or acknowledging the complex market hesitations surrounding Iran, such as financial institutions’ risk aversion. No explicit impact assessments negating the cited studies are referenced.

Policy Directions and Institutional Balance

The Commission’s stance prioritizes maintaining a firm sanctions regime aligned with global security goals, while diplomatically distancing itself from civilian harm through legal exemptions. This approach leans toward preserving the current scope of sanctions without expanding relief measures or addressing private sector overcompliance comprehensively.

Impact on Stakeholders

Iranian patients and humanitarian NGOs face significant challenges due to alleged gaps between sanctions policy and ground realities, possibly deepening health crises. Conversely, EU regulatory bodies uphold sanctions as essential security tools but must manage reputational risks linked to humanitarian critiques. European financial institutions navigate compliance complexities, balancing lawful restrictions with market reputation and operational risks. The EU’s diplomatic posture retains firmness, though with acknowledged tensions against humanitarian concerns.

Next Steps

As per parliamentary procedure, the Commission is expected to provide detailed follow-ups in coming weeks. Their forthcoming communications will likely influence future oversight of sanctions efficacy and humanitarian safeguards, providing critical signals on the EU’s balancing act between geopolitics and people’s welfare.

← Atlas › News › Foreign affairs